News
Garber Announces Advisory Committee for Harvard Law School Dean Search
News
First Harvard Prize Book in Kosovo Established by Harvard Alumni
News
Ryan Murdock ’25 Remembered as Dedicated Advocate and Caring Friend
News
Harvard Faculty Appeal Temporary Suspensions From Widener Library
News
Man Who Managed Clients for High-End Cambridge Brothel Network Pleads Guilty
If you were going to die of organ failure waiting for an organ from a cadaver, would you accept a pig organ instead?
David H. Sachs ’63 is hoping you will.
Over the past two decades, Sachs has surrounded himself with a
handful of the world’s most skilled surgeons and immunologists, as well
has two dozen baboons and several hundred inbred miniature pigs.
In “The Xeno Chronicles,” G. Wayne Miller recounts his two
years spent in Sachs’ laboratory at Massachusetts General Hospital,
where Sachs is the director of the Transplantation Biology Research
Center. The result is a revealing look at Sachs’ attempts to transplant
organs from pigs into baboons, hoping that if a baboon won’t reject the
organ, humans won’t either. And this is where Sachs’ research efforts
lie: investigating new ways to prevent baboons’ immune systems from
attacking the foreign organs, a task that comes with painstakingly slow
progress.
The peek into Sachs’ research group is enlightening at times
and disappointingly stiff at others. Miller profiles each of the major
players in the field: Kazuhiko “Kaz” Yamada, the Japanese master
surgeon; David K.C. Cooper, the old-school British surgeon; and Sachs
himself, a New York native who was nearly crippled by polio in the
1940s. But, save a few revealing outbursts in group meetings, Miller
has trouble getting any of the players to go off-message, quoting
formal-sounding statements in multi-paragraph chunks. They escape from
their interviews with their press armor intact.
Miller casts a wide net of narrative, jumping somewhat
discordantly between scenes of surgery, group meetings, and debilitated
patients who, it’s no surprise, would probably stand to benefit from
xenotransplantation technology. There are, however, areas where the
narrative excels. He recounts an entertaining history of early attempts
at xenotransplantation, most notably the exploits of traveling doctor
John R. Brinkley, a snake-oil pusher of the 1920s. Brinkley’s scam was
convincing hundreds of American men that they could cure impotence (and
restore their all-around vitality) through implanting goat testicles
alongside their own gonads.
“The Xeno Chronicles” raises several interesting questions,
but, in a slim 206 pages, Miller manages an honest stab at only a few
of them. What issues of identity would a pig-organ recipient face? What
are the ethics of growing and harvesting pigs solely for their
organs—and should we transplant said organs into humans who, having
brought themselves to their knees before the medical community, are
sick in the first place because they’ve eaten too many pork chops?
Wisely, Miller extensively ponders the arguments of the animal
rights crowd in a careful analysis of the ethics of
xenotransplantation. In the end, he appears to come down squarely in
Sachs’ camp—that such experiments are not only ethical, but probably
moral as well, given that they advance the human condition. Still,
Miller is appropriately respectful of the opposite position.
“The Xeno Chronicles” leaves the reader with little clue of
what the future of xenotransplantion will hold, and whether
xenotransplantation or stem cell-generated organs will win the race to
supply our species with replacement organs. (The scientific community
generally believes that at least one technique will be successful over
the long haul.) The cliffhanger is warranted, since a snapshot of
scientific research, as Miller provides, will generally give a murky
picture of the future, especially, as in Sachs’ case, when funding is
running perilously low.
But most disappointingly, Miller dances around perhaps the
most important question raised in an examination of biotechnology
research. In a society with limited resources for medical research,
should we primarily fund treatments and short-term cures, such as
xenotransplantation, or should we fund research for preventive measures
and long-term cures, such as stem cell technology? This question is at
the center of today’s debate on biomedical budgeting, and Miller gives
it short thrift. Still, Miller makes us ponder several sticky questions
that face all of medical research, and learning them through
xenotransplantation is at least an interesting path.
—Staff writer Matthew S. Meisel can be reached at meisel@fas.harvard.edu.
Want to keep up with breaking news? Subscribe to our email newsletter.